OncoMatch/Clinical Trials/NCT05183984
Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer
Is NCT05183984 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Chemotherapy and Bevacizumab-Awwb for ovarian cancer.
Treatment: Chemotherapy · Bevacizumab-Awwb · Niraparib — Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 germline deleterious mutation
other epithelial non mucinous and non-clear cell ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation
Required: BRCA2 germline deleterious mutation
other epithelial non mucinous and non-clear cell ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation
Disease stage
Required: Stage FIGO STAGE IIIA, FIGO STAGE IIIB, FIGO STAGE IIIC (2018 FIGO classification)
At an advanced stage: FIGO stage IIIA to IIIC of the 2018 FIGO classification
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin) — frontline
Patient must have received one cycle of carboplatin AUC 5-6 + paclitaxel 175 mg/m²
Must have received: taxane (paclitaxel) — frontline
Patient must have received one cycle of carboplatin AUC 5-6 + paclitaxel 175 mg/m²
Must have received: surgery — frontline, complete cytoreductive surgery (no visible residual disease)
Patient having undergone frontline, complete cytoreductive surgery (i.e. no visible residual disease)
Cannot have received: PARP inhibitor
Any previous treatment with PARP inhibitor
Cannot have received: radiation therapy
Exception: within 6 weeks prior to study treatment
Patient receiving radiotherapy within 6 weeks prior to study treatment
Cannot have received: allogenic bone marrow transplant
Previous allogenic bone marrow transplant
Cannot have received: other simultaneous chemotherapy drugs
Exception: except during a HIPEC procedure with cisplatin at PDS
Administration of other simultaneous chemotherapy drugs - except during a HIPEC procedure with cisplatin at PDS, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroid antiemetics)
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; Platelet count ≥ 100 x 10^9/L
Kidney function
Serum creatinine ≤ 1.5 x institutional ULN and GFR > 50 mL/min
Liver function
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); ASAT/SGOT and ALAT/SGPT ≤ 2.5 x ULN
Patient must have normal organ and bone marrow function before first cycle of chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05183984 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor, radiation therapy, allogenic bone marrow transplant disqualifies patients from enrollment.
Does this trial require BRCA1?
Yes, BRCA1 germline deleterious mutation is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 germline deleterious mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage FIGO STAGE IIIA or FIGO STAGE IIIB or FIGO STAGE IIIC is required.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages